NXTC
NextCure, Inc.
Price Chart
No historical data available
Latest Quote
$6.39
+0.30 (+4.93%)
Current Price
| Previous Close | $6.09 |
| Open | $6.13 |
| Day High | $6.56 |
| Day Low | $6.08 |
| Volume | 54,478 |
Stock Information
| Shares Outstanding | 4.58M |
| Total Debt | $4.67M |
| Cash Equivalents | $20.09M |
| Net Income | $-42.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $29.25M |
| EPS (TTM) | $-8.28 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $13.83M |
| Income | $-42.75M |
| Book/sh | $2.99 |
| Cash/sh | $4.39 |
| Employees | 40 |
Financial Ratios
| Quick Ratio | 3.15 |
| Current Ratio | 3.47 |
| Debt/Eq | 38.41 |
Returns & Margins
| ROA | -69.02% |
| ROE | -204.56% |
Ownership
| Insider Ownership | 8.64% |
| Institutional Ownership | 52.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.08 |
| P/B | 2.14 |
Analyst Data
| Recommendation | none |
| Target Price | $22.50 |
Technical Indicators
| SMA20 | $6.44 |
| SMA50 | $4.64 |
| SMA200 | $9.15 |
| RSI | 45.54 |
| ATR | 0.8277 |
| Shares Float | 2.93M |
| Short Float | 3.24% |
| Short Ratio | 0.03 |
| Volatility | 1.27 |
| Rel Volume | 0.20 |
Performance History
| Week | +1.59% |
| Month | +27.04% |
| Quarter | +3.06% |
| 6 Months | -49.76% |
| YTD | -51.88% |
| Year | +22.06% |
| 3 Years | -65.87% |
| 5 Years | -92.40% |
| 10 Years | -97.32% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
đ° Latest News
No news articles available at the moment. Check back later for updates on NXTC.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $57,616,000 | $57,206,000 | $67,637,000 | $75,909,000 |
| Other Income Expense | $1,772,000 | $1,552,000 | $4,914,000 | $1,176,000 |
| Other Non Operating Income Expenses | $1,772,000 | $4,094,000 | $4,914,000 | $1,176,000 |
| Operating Expense | $57,616,000 | $57,206,000 | $67,637,000 | $75,909,000 |
| General And Administrative Expense | $12,693,000 | $15,718,000 | $19,706,000 | $21,710,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Normalized Income | $-55,844,000 | $-53,112,000 | $-62,723,000 | $-74,733,000 |
| Net Income From Continuing And Discontinued Operation | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Total Operating Income As Reported | $-57,616,000 | $-59,748,000 | $-67,637,000 | $-75,909,000 |
| Net Income Common Stockholders | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Net Income | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Net Income Including Noncontrolling Interests | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Net Income Continuous Operations | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Pretax Income | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Special Income Charges | $0 | $-2,542,000 | $0 | - |
| Operating Income | $-57,616,000 | $-57,206,000 | $-67,637,000 | $-75,909,000 |
| Per Share | ||||
| Diluted EPS | $-19.65 | $-23.88 | $-27.00 | $-32.28 |
| Basic EPS | $-19.65 | $-23.88 | $-27.00 | $-32.28 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-55,431,000 | $-51,799,000 | $-63,953,000 | $-71,785,000 |
| Total Unusual Items | $0 | $-2,542,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-2,542,000 | $0 | - |
| Reconciled Depreciation | $2,185,000 | $2,865,000 | $3,684,000 | $4,124,000 |
| EBITDA (Bullshit earnings) | $-55,431,000 | $-54,341,000 | $-63,953,000 | $-71,785,000 |
| EBIT | $-57,616,000 | $-57,206,000 | $-67,637,000 | $-75,909,000 |
| Diluted Average Shares | $2,842,448 | $2,330,386 | $2,319,715 | $2,312,017 |
| Basic Average Shares | $2,842,448 | $2,330,386 | $2,319,715 | $2,312,017 |
| Diluted NI Availto Com Stockholders | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Restructuring And Mergern Acquisition | $0 | $2,542,000 | $0 | - |
| Research And Development | $44,923,000 | $41,488,000 | $47,931,000 | $54,199,000 |
| Selling General And Administration | $12,693,000 | $15,718,000 | $19,706,000 | $21,710,000 |
| Other Gand A | $12,693,000 | $15,718,000 | $19,706,000 | $21,710,000 |
Fetched: 2026-08-31
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $34,943,000 | $65,472,000 | $114,421,000 | $167,530,000 |
| Total Assets | $50,183,000 | $80,860,000 | $128,038,000 | $184,161,000 |
| Total Non Current Assets | $6,436,000 | $9,053,000 | $15,313,000 | $20,178,000 |
| Other Non Current Assets | $546,000 | $332,000 | $1,882,000 | $3,265,000 |
| Current Assets | $43,747,000 | $71,807,000 | $112,725,000 | $163,983,000 |
| Other Current Assets | $1,929,000 | $3,186,000 | $4,426,000 | $4,072,000 |
| Cash Cash Equivalents And Short Term Investments | $41,818,000 | $68,621,000 | $108,299,000 | $159,911,000 |
| Cash And Cash Equivalents | $25,982,000 | $27,727,000 | $13,082,000 | $26,630,000 |
| Restricted Cash | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $5,153,000 | $5,949,000 | $6,605,000 | $7,123,000 |
| Long Term Debt And Capital Lease Obligation | $4,148,000 | $5,153,000 | $5,949,000 | $6,605,000 |
| Current Debt And Capital Lease Obligation | $1,005,000 | $796,000 | $656,000 | $518,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,240,000 | $15,388,000 | $13,617,000 | $16,631,000 |
| Total Non Current Liabilities Net Minority Interest | $4,674,000 | $5,814,000 | $6,734,000 | $7,504,000 |
| Other Non Current Liabilities | $526,000 | $661,000 | $785,000 | $899,000 |
| Current Liabilities | $10,566,000 | $9,574,000 | $6,883,000 | $9,127,000 |
| Other Current Liabilities | $135,000 | $124,000 | $113,000 | $105,000 |
| Payables And Accrued Expenses | $9,426,000 | $8,654,000 | $6,114,000 | $8,504,000 |
| Payables | $2,011,000 | $5,353,000 | $2,330,000 | $4,270,000 |
| Accounts Payable | $2,011,000 | $5,353,000 | $2,330,000 | $4,270,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $34,943,000 | $65,472,000 | $114,421,000 | $167,530,000 |
| Total Equity Gross Minority Interest | $34,943,000 | $65,472,000 | $114,421,000 | $167,530,000 |
| Stockholders Equity | $34,943,000 | $65,472,000 | $114,421,000 | $167,530,000 |
| Gains Losses Not Affecting Retained Earnings | $21,000 | $4,000 | $-222,000 | $-1,494,000 |
| Other Equity Adjustments | $21,000 | $4,000 | $-222,000 | $-1,494,000 |
| Retained Earnings | $-435,980,000 | $-380,136,000 | $-324,482,000 | $-261,759,000 |
| Other | ||||
| Ordinary Shares Number | $3,505,621 | $2,333,890 | $2,325,252 | $2,314,544 |
| Share Issued | $3,505,621 | $2,333,890 | $2,325,252 | $2,314,544 |
| Tangible Book Value | $34,943,000 | $65,472,000 | $114,421,000 | $167,530,000 |
| Invested Capital | $34,943,000 | $65,472,000 | $114,421,000 | $167,530,000 |
| Working Capital | $33,181,000 | $62,233,000 | $105,842,000 | $154,856,000 |
| Capital Lease Obligations | $5,153,000 | $5,949,000 | $6,605,000 | $7,123,000 |
| Total Capitalization | $34,943,000 | $65,472,000 | $114,421,000 | $167,530,000 |
| Additional Paid In Capital | $470,898,000 | $445,602,000 | $439,097,000 | $430,755,000 |
| Capital Stock | $4,000 | $2,000 | $28,000 | $28,000 |
| Common Stock | $4,000 | $2,000 | $28,000 | $28,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $4,148,000 | $5,153,000 | $5,949,000 | $6,605,000 |
| Current Capital Lease Obligation | $1,005,000 | $796,000 | $656,000 | $518,000 |
| Current Accrued Expenses | $7,415,000 | $3,301,000 | $3,784,000 | $4,234,000 |
| Net PPE | $5,890,000 | $8,721,000 | $13,431,000 | $16,913,000 |
| Accumulated Depreciation | $-25,280,000 | $-23,095,000 | $-20,229,000 | $-16,630,000 |
| Gross PPE | $31,170,000 | $31,816,000 | $33,660,000 | $33,543,000 |
| Leases | $9,309,000 | $9,309,000 | $9,309,000 | $9,336,000 |
| Other Properties | $20,767,000 | $21,413,000 | $23,032,000 | $22,260,000 |
| Machinery Furniture Equipment | $1,094,000 | $1,094,000 | $1,094,000 | $1,094,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $15,836,000 | $40,894,000 | $95,217,000 | $133,281,000 |
| Construction In Progress | - | $0 | $225,000 | $853,000 |
Fetched: 2026-08-31
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-49,613,000 | $-41,279,000 | $-53,794,000 | $-56,002,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-49,613,000 | $-40,805,000 | $-52,974,000 | $-53,886,000 |
| Cash Flow From Continuing Operating Activities | $-49,613,000 | $-40,805,000 | $-52,974,000 | $-53,886,000 |
| Operating Gains Losses | - | - | - | $87,000 |
| Investing Activities | ||||
| Investing Cash Flow | $25,556,000 | $55,306,000 | $39,272,000 | $67,979,000 |
| Cash Flow From Continuing Investing Activities | $25,556,000 | $55,306,000 | $39,272,000 | $67,979,000 |
| Capital Expenditure | - | $-474,000 | $-820,000 | $-2,116,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $22,276,000 | $39,000 | $5,000 | - |
| Financing Cash Flow | $22,312,000 | $144,000 | $154,000 | $200,000 |
| Cash Flow From Continuing Financing Activities | $22,312,000 | $144,000 | $154,000 | $200,000 |
| Net Common Stock Issuance | $22,276,000 | $39,000 | $5,000 | - |
| Common Stock Issuance | $22,276,000 | $39,000 | $5,000 | - |
| Other | ||||
| Interest Paid Supplemental Data | $62,000 | $72,000 | $81,000 | $90,000 |
| End Cash Position | $25,982,000 | $27,727,000 | $13,082,000 | $26,630,000 |
| Beginning Cash Position | $27,727,000 | $13,082,000 | $26,630,000 | $12,337,000 |
| Changes In Cash | $-1,745,000 | $14,645,000 | $-13,548,000 | $14,293,000 |
| Proceeds From Stock Option Exercised | $36,000 | $105,000 | $149,000 | $200,000 |
| Net Investment Purchase And Sale | $25,556,000 | $55,780,000 | $40,092,000 | $70,095,000 |
| Sale Of Investment | $52,261,000 | $104,228,000 | $113,597,000 | $104,739,000 |
| Purchase Of Investment | $-26,705,000 | $-48,448,000 | $-73,505,000 | $-34,644,000 |
| Net PPE Purchase And Sale | $0 | $-474,000 | $-820,000 | $-2,116,000 |
| Purchase Of PPE | $0 | $-474,000 | $-820,000 | $-2,116,000 |
| Change In Working Capital | $954,000 | $4,532,000 | $-1,940,000 | $3,725,000 |
| Change In Other Current Liabilities | $-1,140,000 | $-920,000 | $-770,000 | $0 |
| Change In Payables And Accrued Expense | $992,000 | $2,691,000 | $-2,244,000 | $1,687,000 |
| Change In Accrued Expense | $4,334,000 | $-332,000 | $-304,000 | $-641,000 |
| Change In Payable | $-3,342,000 | $3,023,000 | $-1,940,000 | $2,328,000 |
| Change In Account Payable | $-3,342,000 | $3,023,000 | $-1,940,000 | $2,328,000 |
| Change In Prepaid Assets | $1,102,000 | $2,761,000 | $1,074,000 | $2,038,000 |
| Other Non Cash Items | $587,000 | $561,000 | $573,000 | $356,000 |
| Stock Based Compensation | $2,986,000 | $6,335,000 | $8,188,000 | $9,508,000 |
| Asset Impairment Charge | $0 | $1,786,000 | $0 | - |
| Amortization Of Securities | $-481,000 | $-1,230,000 | $-756,000 | $3,047,000 |
| Depreciation Amortization Depletion | $2,185,000 | $2,865,000 | $3,684,000 | $4,124,000 |
| Depreciation And Amortization | $2,185,000 | $2,865,000 | $3,684,000 | $4,124,000 |
| Net Income From Continuing Operations | $-55,844,000 | $-55,654,000 | $-62,723,000 | $-74,733,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $87,000 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Income Tax Paid Supplemental Data | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-08-31